[NICE Technology Appraisal Guidance] Nivolumab with ipilimumab for untreated advanced renal cell carcinoma

NICE |  May 2019 | Nivolumab with ipilimumab for untreated advanced renal cell carcinoma

Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma that is intermediate- or poor-risk in adults (Source: NICE).

Full details from NICE

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s